MUTYH Gene Mutation Analysis (Y165C and G382D) for MUTYH associated polyposis (MAP)
MUTYH gene is located in the short arm of chromosome 1 at position p34.1. It encodes for the enzyme MYH glycosylase which is responsible for DNA repair via the base excision repair (BER) mechanism. In normal subjects, adenine is paired with thymine in DNA, but sometimes, guanine may pair with adenine, forming an incorrect base pair. MYH glycosylase specifically removes adenine from adenine-guanine pairs in the DNA. Failure to repair these adenine-guanine pairs results in the accumulation of such errors and is felt to be important in the pathogenesis of leading to adenomatous polyps and cancers of the colon.
MUTYH mutations are transmitted in an autosomal recessive fashion. Parents of an affected individual each carry one mutated gene and the affected offspring received both mutated copies. Studies have shown that 1 in every 100 individuals may carry an MUTYH mutation. Y165C and G382D are the two common variants that cause patients to develop multiple (>10 - < 100) colonic adenomatous polyps and an increased risk of colorectal cancer (CRC). Patients with MAP may be homozygotes or compound heterozygotes for pathogenic germline variants of MUTYH.
Patients with MAP develop from 10-100 adenomatous polyps at an early age. Although adenomatous polyps are benign by definition, with additional mutations they will typically transform into colorectal cancer by the third to fifth decade of life. Therefore these patients are typically monitored annually or biannually with colonoscopy for the development of cancer. Patients with CRC or numerous polyps may undergo partial or total colectomy to avoid future cancer development.
- Aids in the diagnosis of MUYTH-associated polyposis in patients with multiple adenomas
- Aid in identifying carriers and affected individuals in the same family
A positive result confirms the presence of Y165C and/or G382D variants in the MYH gene.
A negative result indicates the absence of mutation or pathogenic variants in the MYH gene.
Negative for mutations analyze (No mutations or pathogenic variants in the MYH gene were detected)
Polymerase Chain Reaction (PCR) for Y165C and/or G382D variants, Multiplex Ligation-dependent Probe Amplification (MLPA), and sequence analysis by Next Generation Sequencing (NGS)/ Massively Parallel Sequencing (MPS).
Whole blood (EDTA) or (ACD).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: unacceptable
Carcinoembryonic antigen (CEA), occult blood, Microsatellite instability testing (MSI), germline testing for pathogenic MMR gene variants, biopsy, Immunohistochemistry of tumor tissue, MLH1/MSH2/MSH6/PMS2 gene mutation analysis, and in-vitro MMR gene assays.
1-2 weeks.
- JAMA. 2012; 8:485-492 [PMID: 22851115]
- Clin Cancer Res. 2014;3: 58-68 [PMID: 24470512]
- GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022 [PMID: 23035301]
- Hered Cancer Clin Pract. 2005; 5: 65-70 [PMID: 20223032]